How to evaluate the ecologic impact of antibiotics in phase III trials.
Carbon
C
C
Service de Médecine Interne, EMI-U 9933, Hôpital Bichat, Paris, France. claude.carbon@bch.ap-hop-paris.fr
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003428:Cross Infection / Q000517:prevention & control; D017753:Ecosystem; D005069:Evaluation Studies as Topic; D006801:Humans; D011237:Predictive Value of Tests; D012107:Research Design
D000900:Anti-Bacterial Agents